An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Lupartumab amadotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 08 Mar 2018 Planned number of patients changed from 142 to 117.
- 08 Mar 2018 Planned End Date changed from 31 Dec 2018 to 30 Apr 2020.
- 08 Mar 2018 Planned primary completion date changed from 31 Dec 2018 to 30 Apr 2020.